372 related articles for article (PubMed ID: 35127528)
1. Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy.
Yang G; Xie J; Zhang S; Gu W; Yuan J; Wang R; Guo C; Ye L; Peng B; Yao X; Yang B
Front Oncol; 2021; 11():812549. PubMed ID: 35127528
[TBL] [Abstract][Full Text] [Related]
2. Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.
Mandel PC; Huland H; Tiebel A; Haese A; Salomon G; Budäus L; Tilki D; Chun F; Heinzer H; Graefen M; Pantel K; Riethdorf S; Steuber T
Eur Urol Focus; 2021 Jan; 7(1):55-62. PubMed ID: 31178293
[TBL] [Abstract][Full Text] [Related]
3. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
4. Perioperative change of circulating tumor cells in cytoreductive radical prostatectomy for oligometastatic hormone-sensitive prostate cancer: the preliminary safety evidence from long-term oncologic outcomes.
Maskey N; Mao S; Yang G; Guo Y; Kadier A; Yuan J; Xie J; Guo C; Yang B; Yao X
Int Urol Nephrol; 2023 Jul; 55(7):1709-1717. PubMed ID: 37160485
[TBL] [Abstract][Full Text] [Related]
5. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients.
Kohli M; Li J; Du M; Hillman DW; Dehm SM; Tan W; Carlson R; Campion MB; Wang L; Wang L; Zhang H; Zhang P; Kilari D; Huang CC; Wang L
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):411-418. PubMed ID: 29858592
[TBL] [Abstract][Full Text] [Related]
6. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
Davies CR; Guo T; Burke E; Stankiewicz E; Xu L; Mao X; Scandura G; Rajan P; Tipples K; Alifrangis C; Wimalasingham AG; Galazi M; Crusz S; Powles T; Grey A; Oliver T; Kudahetti S; Shaw G; Berney D; Shamash J; Lu YJ
Front Oncol; 2022; 12():1060864. PubMed ID: 36727071
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma.
Yang X; Ni H; Lu Z; Zhang J; Zhang Q; Ning S; Qi L; Xiang B
BMC Cancer; 2023 Jan; 23(1):10. PubMed ID: 36600214
[TBL] [Abstract][Full Text] [Related]
8. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of epithelial-mesenchymal transition typing of circulating tumour cells in colorectal cancer.
Hou J; Guo C; Lyu G
Colorectal Dis; 2020 May; 22(5):581-587. PubMed ID: 31868956
[TBL] [Abstract][Full Text] [Related]
10. Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer.
Wang C; Zhang Z; Chong W; Luo R; Myers RE; Gu J; Lin J; Wei Q; Li B; Rebbeck TR; Lu-Yao G; Kelly WK; Yang H
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33450815
[TBL] [Abstract][Full Text] [Related]
11. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.
Yang YJ; Kong YY; Li GX; Wang Y; Ye DW; Dai B
BJU Int; 2019 Aug; 124(2):258-267. PubMed ID: 30536520
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Therapeutic Significance of Circulating Tumor Cell Phenotype Detection Based on Epithelial-Mesenchymal Transition Markers in Early and Midstage Colorectal Cancer First-Line Chemotherapy.
Lu G; Lu Z; Li C; Huang X; Luo Q
Comput Math Methods Med; 2021; 2021():2294562. PubMed ID: 34777560
[TBL] [Abstract][Full Text] [Related]
13. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cell surface vimentin positive circulating tumor cells as a prognostic biomarker for stage III/IV colorectal cancer.
Yu J; Yang M; Peng T; Liu Y; Cao Y
Sci Rep; 2023 Nov; 13(1):18791. PubMed ID: 37914786
[TBL] [Abstract][Full Text] [Related]
15. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells with epithelial-mesenchymal transition markers as potential biomarkers for the diagnosis of lung cancer.
Jiang SS; Mao CG; Feng YG; Jiang B; Tao SL; Tan QY; Deng B
World J Clin Cases; 2021 Apr; 9(12):2721-2730. PubMed ID: 33969055
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Su P; Lai W; Liu L; Zeng Y; Xu H; Lan Q; Chu Z; Chu Z
Clin Transl Gastroenterol; 2020 Dec; 11(12):e00265. PubMed ID: 33512811
[TBL] [Abstract][Full Text] [Related]
18. PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer.
Gupta S; Halabi S; Yang Q; Roy A; Tubbs A; Gore Y; George DJ; Nanus DM; Antonarakis ES; Danila DC; Szmulewitz RZ; Wenstrup R; Armstrong AJ
Clin Cancer Res; 2023 May; 29(10):1929-1937. PubMed ID: 36897758
[TBL] [Abstract][Full Text] [Related]
19. Association of circulating tumor cells and
Dai S; Shao X; Wei Q; Du S; Hou C; Li H; Jin D
Front Oncol; 2023; 13():819357. PubMed ID: 36937398
[TBL] [Abstract][Full Text] [Related]
20. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
